e5765c1c17
- Source: inbox/queue/2026-04-13-calibrate-glp1-behavioral-interrupted-access-outcomes.md - Domain: health - Claims: 0, Entities: 1 - Enrichments: 1 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
45 lines
No EOL
1.9 KiB
Markdown
45 lines
No EOL
1.9 KiB
Markdown
# Calibrate
|
|
|
|
**Type:** Company
|
|
**Domain:** Health
|
|
**Status:** Active
|
|
**Business Model:** Employer-sponsored GLP-1 + behavioral coaching program
|
|
**Market Position:** Premium-tier weight management program ($200-300+/month depending on employer negotiation)
|
|
|
|
## Overview
|
|
|
|
Calibrate operates an employer-sponsored weight management program combining GLP-1 prescriptions with behavioral coaching across four pillars: food, sleep, exercise, and emotional health. The program targets commercially insured, higher-income populations through employer plans.
|
|
|
|
## Program Structure
|
|
|
|
- GLP-1 prescriptions
|
|
- Coaching on food, sleep, exercise, emotional health (four pillars)
|
|
- Regular check-ins and goal tracking
|
|
- Weekly weight tracking (80% member engagement)
|
|
- Coaching session completion (67% member engagement)
|
|
|
|
## Key Metrics
|
|
|
|
**Sample size:** n=17,475 members (Endocrine Society 2025 data)
|
|
|
|
**Primary outcomes (uninterrupted access):**
|
|
- 12-month weight loss: 15.7% average
|
|
- 18-month: 17.3%
|
|
- 24-month: 17.9% (continued loss, not plateau)
|
|
- Waist circumference reduction: avg 6 inches at 12 months
|
|
|
|
**Interrupted access outcomes:**
|
|
- 12-month weight loss: 13.7% (vs. 17% uninterrupted)
|
|
- 24-month: 14.9% (vs. 20.1% uninterrupted)
|
|
- Delta: ~2.2 percentage points at 12 months; ~5.2 percentage points at 24 months
|
|
|
|
## Timeline
|
|
|
|
- **2025-01-01** — Presented interrupted access data at Endocrine Society 2025 showing behavioral coaching creates durability floor: members with treatment interruptions maintained 13.7% weight loss at 12 months vs. standard GLP-1 cessation pattern of ~2/3 weight regain
|
|
|
|
## Notes
|
|
|
|
- "Treatment interruptions" criteria not publicly specified
|
|
- Endocrine Society presentation not yet peer-reviewed as standalone paper
|
|
- No control condition (Calibrate members without behavioral coaching) to isolate behavioral program effect
|
|
- Sample entirely employer-sponsored, skewing toward commercially insured, higher-income populations |